MetaCap

Grifols S.A. (GRFS) vs Supernus (SUPN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Grifols S.A. (GRFS) has outperformed Supernus (SUPN) over the past year, losing 3.0% versus a loss of 36.9%. Over five years, SUPN leads with a -6.5% price change compared with -25.3% for GRFS. Supernus is the larger company by market cap ($5.94 billion vs $5.55 billion), about 1.1 times the size.

On valuation, Grifols S.A. trades at a lower forward P/E (6.6x vs 7.1x for Supernus).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRFS-2.98%SUPN-36.87%
+28%-9%-46%
Nov 21, 20251 yearNov 20, 2026
GRFS-31.40%SUPN-14.52%
+70%+8%-54%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRFS versus SUPN key metrics
MetricGRFSSUPN
Share price$8.15$28.61
Market cap$5.55B$5.94B
1-day change-0.61%+0.92%
YTD return-12.83%-42.43%
1-year return-2.98%-36.87%
5-year return-25.30%-6.53%
P/E ratio (TTM)9.82—
Forward P/E6.557.15
EPS (TTM)$0.83$-0.76
Dividend yield1.30%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$718.95M
Revenue growth (YoY)—+8.63%
Net income (latest FY)—$-38.55M
Gross margin—89.63%
Operating margin—-8.66%
Net margin—-5.36%
52-week high$9.77$42.81
52-week low$6.96$25.92
Distance from 52-week high-16.58%-33.17%
Analyst consensusbuystrong_buy
Avg. price target upside+27.24%+89.23%
Average volume628.64K2.77M
Shares outstanding258.22M207.72M
Employees25,000827
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRFS has outperformed SUPN by 33.9 percentage points over the past year.
  • Grifols S.A. offers a meaningfully higher dividend yield (1.30% vs 0.00%).

About Grifols S.A.

GRFS stock →

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.

Health Care · Biotechnology: Pharmaceutical Preparations · 25,000 employees

About Supernus

SUPN stock →

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees

GRFS vs SUPN FAQ

Which is bigger, Grifols S.A. or Supernus?

Supernus (SUPN) is larger, with a market capitalization of $5.94B compared with $5.55B for Grifols S.A. (GRFS).

Which stock has performed better over the past year, GRFS or SUPN?

GRFS returned -2.98% over the past 12 months, compared with -36.87% for SUPN (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Grifols S.A. or Supernus?

Grifols S.A. pays a dividend yielding 1.30%, while Supernus does not currently pay a regular dividend.

Are Grifols S.A. and Supernus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons